CORRESPONDENCE OPEN
Da a umumab, ca filzomib, and dexame hasone in elapsed o
e ac o y myeloma: final analysis o PLEIADES and EQUULEUS
© The Au ho (s) 2023
Blood Cance Jou nal (2023) 13:33 ; h ps://doi.o g/
10.1038/s41408-023-00805-x
INTRODUCTION
Da a umumab is app o ed in many coun ies as mono he apy and
in combina ion egimens o elapsed/ e ac o y mul iple mye-
loma (RRMM) and newly diagnosed mul iple myeloma [1–3].
Da a umumab-based combina ions ha e also demons a ed
encou aging e ficacy in lenalidomide- e ac o y RRMM [4,5].
Ca filzomib is app o ed as mono he apy and in combina ion
egimens, including da a umumab and dexame hasone (D-Kd), o
RRMM [6]. In he phase 3 CANDOR s udy, D-Kd (in a enous [IV]
da a umumab; ca filzomib 56 mg/m
2
wice weekly) imp o ed
p og ession- ee su i al (PFS) e sus Kd in he o e all popula ion
and lenalidomide- e ac o y pa ien s [7,8]. In he phase
3 A.R.R.O.W. s udy, once-weekly ca filzomib (70 mg/m
2
) signifi-
can ly p olonged PFS e sus wice-weekly ca filzomib (27 mg/m
2
),
p o iding a sa e and mo e con enien Kd dosing egimen [9].
P elimina y esul s om he phase 2 PLEIADES s udy (median
ollow-up, 9.2 mon hs) and he phase 1b EQUULEUS s udy
(median ollow-up, 16.6 mon hs) showed ha combining sub-
cu aneous da a umumab (DARA SC) and da a umumab IV,
espec i ely, wi h Kd (ca filzomib 70 mg/m
2
weekly) was well
ole a ed and induced deep esponses in RRMM pa ien s [10,11].
We epo final da a om PLEIADES and EQUULEUS, wi h a median
ollow-up o 12.4 and 23.7 mon hs, espec i ely.
METHODS
PLEIADES (ClinicalT ials.go Iden ifie : NCT03412565) e alua ed
DARA SC (da a umumab 1800 mg co- o mula ed wi h ecombinan
human hyalu onidase PH20 [ HuPH20; 2000 U/mL; ENHANZE
®
d ug
deli e y echnology, Halozyme, Inc., San Diego, CA, USA]) plus
weekly Kd (ca filzomib 70 mg/m
2
; dexame hasone 40 mg) in RRMM
pa ien s wi h 1 p io line o lenalidomide-based he apy. EQUULEUS
(NCT01998971) e alua ed da a umumab IV plus weekly Kd
(ca filzomib 70 mg/m
2
; dexame hasone 40 mg) in RRMM pa ien s
a e 1 o 3 p io lines o he apy (including bo ezomib and an
immunomodula o y d ug). Pa ien s in bo h s udies ecei ed 28-day
cycles o D-Kd un il disease p og ession. P ima y endpoin s we e
he o e all esponse a e (ORR) in PLEIADES and sa e y and
ole abili y in EQUULEUS. Supplemen a y In o ma ion includes
addi ional me hodology.
RESULTS
A o al o 66 and 85 pa ien s ecei ed D-Kd in PLEIADES and
EQUULEUS, espec i ely. Pa ien demog aphic and baseline cha -
ac e is ics a e summa ized in Table S1. In PLEIADES and EQUULEUS,
he median ( ange) age was 61 (42–84) and 66 (38–85) yea s,
espec i ely, 16/44 (36.4%) and 13/67 (19.4%) pa ien s had high- isk
cy ogene ics, and 41 (62.1%) and 51 (60.0%) we e lenalidomide-
e ac o y. Pa ien s in PLEIADES and EQUULEUS had ecei ed a
median ( ange) o 1 (1–1) and 2 (1–4) p io lines o he apy,
espec i ely, and 60 (90.9%) and 85 (100%) pa ien s had ecei ed
p io p o easome inhibi o he apy. In PLEIADES and EQUULEUS,
31 (47.0%) and 50 (58.8%) pa ien s, espec i ely, discon inued
ea men , p ima ily due o p og essi e disease. Median ( ange)
ea men du a ion was 12.0 (0–21) mon hs in PLEIADES and
19.8 (0.3–34.5) mon hs in EQUULEUS. Pa ien disposi ion and d ug
exposu e a e u he desc ibed in Supplemen a y In o ma ion.
Pha macokine ic da a a e p o ided o pha macokine ic-
e aluable popula ions (PLEIADES, n=65; EQUULEUS, n=85 [single
fi s dose, n=10; spli fi s dose, n=75]). The maximum
concen a ion o DARA SC was obse ed on Cycle 1, Day 4 a e
he fi s dose o Cycle 3, Day 4 a e he nin h dose. Fo
da a umumab IV, he maximum concen a ion was obse ed on
Cycle 1, Day 1 (end o in usion) a e he fi s dose o Cycle 3, Day 1
(end o in usion) a e he nin h dose. In bo h s udies, se um ough
concen a ion (C
ough
) inc eased o maximum C
ough
on Cycle 3,
Day 1 p e-dose, hen dec eased wi h less equen dosing. DARA SC
p o ided nume ically highe C
ough
(wi hin a simila ange) e sus
da a umumab IV. Subg oup analysis o se um da a umumab
concen a ion based on body weigh in PLEIADES is p esen ed in
Table S2. In EQUULEUS, pha macokine ic p ofiles o single and spli
fi s da a umumab doses we e simila om Cycle 2, Day 1 p e-
in usion onwa d (Table S3). No pa ien in he immunogenici y-
e aluable popula ion o ei he s udy es ed posi i e o an i-
da a umumab an ibodies. In PLEIADES, 3/64 (4.7%) pa ien s in he
HuPH20 immunogenici y-e aluable popula ion had ea men -
eme gen an i- HuPH20 an ibodies a e DARA SC adminis a ion;
none we e neu alizing.
The mos common any-g ade and g ade 3/4 ea men -
eme gen ad e se e en s (TEAEs) in PLEIADES a e summa ized in
Table 1. G ade 3/4 in ec ions occu ed in 9 (13.6%) pa ien s, mos
commonly pneumonia (4.5%). Se ious TEAEs we e epo ed in 22
(33.3%) pa ien s, mos commonly pneumonia (4.5%). One (1.5%)
pa ien discon inued ea men due o a TEAE. Th ee pa ien s had
g ade 5 TEAEs: 1 each wi h COVID-19 pneumonia, sepsis, and
espi a o y ailu e.
The mos common any-g ade and g ade 3/4 TEAEs in
EQUULEUS a e summa ized in Table 1. G ade 3/4 in ec ions we e
epo ed in 18 (21.2%) pa ien s, mos commonly pneumonia
(4.7%). Se ious TEAEs occu ed in 41 (48.2%) pa ien s, mos
commonly basal cell ca cinoma, pneumonia, and uppe espi a-
o y ac in ec ion (4.7% each). Fi e (5.9%) pa ien s discon inued
ea men due o TEAEs. Th ee pa ien s had g ade 5 TEAEs: wo
wi h gene al physical heal h de e io a ion and one wi h mul iple
o gan dys unc ion synd ome.
Two (3.0%) pa ien s in PLEIADES had g ade 3/4 ca diac TEAEs: one
each wi h g ade 3 ca diac ailu e and g ade 4 le en icula
Recei ed: 3 Oc obe 2022 Re ised: 24 Feb ua y 2023 Accep ed: 27 Feb ua y 2023
www.na u e.com/bcj
Blood Cance Jou nal
1234567890();,:
dys unc ion. In EQUULEUS, 9 (10.6%) pa ien s had g ade 3/4 ca diac
TEAEs, including sinus achyca dia, ca diac ailu e, sys olic dys unc-
ion (n=2 each) and a ial fib illa ion, conges i e ca diomyopa hy,
le en icula ailu e, myoca dial ischemia, and myoca di is (n=1
each). In bo h s udies, he median le en icula ejec ion ac ion
did no no ably change o e ime om baseline. Addi ional de ails
a e included in Supplemen a y In o ma ion.
Th ee (4.5%) pa ien s had in usion- ela ed eac ions (IRRs) wi h
DARA SC in PLEIADES; wo had g ade 3 IRRs. All pa ien s wi h IRRs
expe ienced hem on he fi s adminis a ion; he median ( ange)
ime o IRR onse was 65 (4–75) min. Local injec ion-si e eac ions
occu ed in 7 (10.6%) pa ien s; all we e g ade 1/2. In EQUULEUS,
6 (60.0%) pa ien s who ecei ed a single fi s dose and 31 (41.3%)
who ecei ed a spli fi s dose had IRRs wi h da a umumab IV.
Mos IRRs we e mild (2 pa ien s had g ade 3/4 IRRs) and occu ed
du ing he fi s in usion. Fi e (50.0%) pa ien s expe ienced IRRs
du ing Cycle 1, Day 1 wi h a single fi s da a umumab dose; 27
(36.0%) expe ienced IRRs du ing Cycle 1, Day 1 wi h a spli fi s
da a umumab dose.
In PLEIADES (median [ ange] ollow-up, 12.4 [0.2–20.6] mon hs),
ORR was 84.8% in he all- ea ed popula ion and 84.1% in
lenalidomide- e ac o y pa ien s (Fig. 1). ORR was 75.0% (12/16)
and 82.1% (23/28) in pa ien s wi h high and s anda d cy ogene ic
isk, espec i ely. The median du a ion o esponse was no
Table 1. Mos common any-g ade (≥25%) and g ade 3/4 (≥5%) TEAEs wi h D-Kd in he PLEIADES and EQUULEUS s udies.
PLEIADES D-Kd (n=66) EQUULEUS D-Kd (n=85)
Any-g ade G ade 3/4 Any g ade G ade 3/4
TEAEs, n(%) 66 (100) 49 (74.2) 85 (100) 67 (78.8)
Hema ologic
Th ombocy openia 34 (51.5) 13 (19.7) 58 (68.2) 27 (31.8)
Anemia 25 (37.9) 8 (12.1) 44 (51.8) 18 (21.2)
Neu openia 15 (22.7) 7 (10.6) 26 (30.6) 18 (21.2)
Lymphopenia 12 (18.2) 8 (12.1) 25 (29.4) 21 (24.7)
Nonhema ologic
Hype ension 23 (34.8) 14 (21.2) 28 (32.9) 17 (20.0)
Insomnia 23 (34.8) 4 (6.1) 28 (32.9) 4 (4.7)
Dia hea 20 (30.3) 0 32 (37.6) 2 (2.4)
Nausea 17 (25.8) 0 36 (42.4) 1 (1.2)
Nasopha yngi is 17 (25.8) 0 15 (17.6) 0
Headache 15 (22.7) 0 23 (27.1) 1 (1.2)
Py exia 14 (21.2) 1 (1.5) 31 (36.5) 1 (1.2)
As henia 14 (21.2) 0 36 (42.4) 13 (15.3)
Cough 13 (19.7) 0 24 (28.2) 0
Dyspnea 12 (18.2) 1 (1.5) 30 (35.3) 3 (3.5)
Uppe espi a o y ac in ec ion 12 (18.2) 0 38 (44.7) 3 (3.5)
Vomi ing 11 (16.7) 0 34 (40.0) 1 (1.2)
D-Kd da a umumab/ca filzomib/dexame hasone, TEAE ea men -eme gen ad e se e en .
PRVGPRCRsCR
PLEIADES D-Kd
(n = 66)
PLEIADES D-Kd
lenalidomide- e ac o y
(n = 44)
EQUULEUS D-Kd
(n = 85)
EQUULEUS D-Kd
lenalidomide- e ac o y
(n = 51)
0
20
40
60
80
100
ORR, %
19.7
22.7
34.8
7.6
18.2
18.2
36.4
11.4
21.2
14.1
32.9
12.9
17.6
13.7
33.3
9.8
84.8% 84.1% 81.2%
74.5%
≥CR:
42.4%
≥VGPR:
77.3%
≥CR:
36.4%
≥VGPR:
72.7%
≥CR:
35.3%
≥VGPR:
68.2%
≥CR:
31.4%
≥VGPR:
64.7%
Fig. 1 Response a es in all pa ien s and lenalidomide- e ac o y pa ien s ea ed wi h D-Kd in PLEIADES o EQUULEUS. Da a we e shown
o he all- ea ed popula ion. No e: Due o ounding, pe cen ages may no add up o he o al pe cen age o each ca ego y. CR comple e
esponse, D-Kd da a umumab/ca filzomib/dexame hasone, ORR o e all esponse a e, PR pa ial esponse, sCR s ingen comple e esponse,
VGPR e y good pa ial esponse.
Co espondence
2
Blood Cance Jou nal (2023) 13:33
eached; he 9-mon h du a ion o esponse a e was 85.4%. PFS
and o e all su i al (OS) we e no analyzed.
In EQUULEUS (median [ ange] ollow-up, 23.7 [0.5–34.7]
mon hs), ORR was 81.2% in he all- ea ed popula ion and 74.5%
in lenalidomide- e ac o y pa ien s (Fig. 1). The median du a ion o
esponse was 27.5 mon hs; he 9-mon h du a ion o esponse a e
was 88.3%. Median PFS was 25.7 mon hs in he all- ea ed
popula ion (Fig. S1A) and 22.3 mon hs in lenalidomide- e ac o y
pa ien s; es ima ed 24-mon h PFS a es we e 52.7% and 46.9%,
espec i ely. The median ime o subsequen an i-cance he apy
was 29.2 mon hs. Median OS was no eached; he es ima ed 24-
mon h OS a e was 71.2% (Fig. S1B).
DISCUSSION
Wi h addi ional ollow-up in PLEIADES and EQUULEUS, no new
sa e y conce ns we e iden ified, and he o e all sa e y p ofile o
D-Kd was consis en be ween s udies. As p e iously demons a ed,
lowe IRR a es and sho e adminis a ion imes we e obse ed wi h
he DARA SC–based e sus da a umumab IV–based egimen. In
EQUULEUS, spli fi s da a umumab dosing p oduced simila sa e y
and pha macokine ic p ofiles as a single fi s dose om Cycle 2, Day
1 p e-in usion onwa d and dec eased median in usion du a ion on
Cycle 1, Day 1, which may imp o e pa ien con enience. Following
weekly dosing, C
ough
o da a umumab a Cycle 3, Day 1 p e-dose
was nume ically highe (wi hin a simila ange) wi h DARA SC e sus
da a umumab IV. DARA SC adminis a ion achie ed adequa e and
consis en exposu e o all body weigh subg oups. The incidence o
ea men -eme gen an i-da a umumab an ibodies was 0% in bo h
s udies, indica ing a low isk o immunogenici y o D-Kd. The
incidence o ea men -eme gen HuPH20 an ibodies was consis-
en wi h o he DARA SC s udies [12,13].
Final analysis esul s om bo h s udies showed D-Kd consis-
en ly induced deep esponses ega dless o lenalidomide
e ac o iness. ORRs in PLEIADES and EQUULEUS we e compa -
able (84.8% and 81.2%, espec i ely). Encou aging 24-mon h PFS
and OS a es o 52.7 and 71.2%, espec i ely, we e demons a ed
in EQUULEUS.
C oss- ial compa isons should be in e p e ed cau iously due o
s udy di e ences. The phase 3 CANDOR s udy [8] compa ed
da a umumab IV plus Kd e sus Kd in RRMM pa ien s wi h 1 o 3
p io lines o he apy. Pa ien s in CANDOR ecei ed ca filzomib
56 mg/m
2
wice weekly (mon hly cumula i e dose, 336 mg/m
2
[Cycle 1, 264 mg/m
2
]), while pa ien s in PLEIADES and EQUULEUS
ecei ed ca filzomib 70 mg/m
2
weekly (mon hly cumula i e dose,
210 mg/m
2
[Cycle 1, 160 mg/m
2
]; ie, 62.5% o CANDOR mon hly
dose). A highe p opo ion o pa ien s in PLEIADES and EQUULEUS
had p io lenalidomide exposu e (100% and 95%, espec i ely) o
we e e ac o y o lenalidomide (62% and 60%) e sus he
CANDOR D-Kd a m (39% and 32%, espec i ely). ORRs in PLEIADES
(84.8%) and EQUULEUS (81.2%) we e compa able o ha epo ed
a a median ollow-up o 27.8 mon hs in he CANDOR D-Kd a m
(84%), wi h highe comple e esponse o be e a es (42.4% and
35.3% s 33%, espec i ely). Median PFS was simila be ween he
D-Kd a ms o EQUULEUS and CANDOR (25.7 and 28.6 mon hs,
espec i ely) [8]. O e all, D-Kd demons a ed e ficacy in PLEIADES,
EQUULEUS, and CANDOR, suppo ing i s use o RRMM, including
lenalidomide- e ac o y mul iple myeloma. Sa e y p ofiles we e
gene ally simila wi h D-Kd u ilizing weekly ca filzomib dosing in
PLEIADES and EQUULEUS and wice-weekly ca filzomib dosing
in CANDOR; howe e , he incidence o a al TEAEs was lowe in
PLEIADES (3/66 [4.5%]) and EQUULEUS (3/85 [3.5%]) compa ed o
he CANDOR D-Kd a m (27/308 [8.8%]) [8]. Resul s om he phase
3 A.R.R.O.W. s udy also ein o ce he a o able benefi - isk p ofile
o once-weekly ca filzomib dosing compa ed wi h a wice-weekly
ea men schedule [9]. Once-weekly ca filzomib dosing may
imp o e cos -e ec i eness and con enience o pa ien s and
heal hca e p o ide s [14].
Limi a ions o PLEIADES and EQUULEUS include small sample
sizes and lack o compa a o a ms. Also, pa ien s in PLEIADES we e
only ollowed o up o 8 weeks a e he las s udy ea men ;
he e o e, PFS and OS we e no e alua ed.
In conclusion, D-Kd con inues o be well ole a ed and e ec i e
in RRMM pa ien s, including lenalidomide- e ac o y pa ien s. Final
analysis esul s om PLEIADES and EQUULEUS u he suppo
D-Kd as a s anda d ea men egimen o RRMM.
Philippe Mo eau
1
✉, Ajai Cha i
2
, Albe O iol
3
,
Joaquin Ma inez-Lopez
4
, Ma hias Haenel
5
, Cy ille Touzeau
1
,
Sikande Ailawadhi
6
, B i a Beseme
7
,
Ja ie de la Rubia Comos
8,9
, C is ina Encinas
10
,
Ma ia-Vic o ia Ma eos
11
, Hans Salwende
12
,
Paula Rod iguez-O e o
13
, Cy ille Hulin
14
, Lionel Ka lin
15
,
Anna Su eda Bala i
16
, Joan Ba gay
17
, Lo fiBenboubke
18
,
Lau a Rosiñol
19
, S e ano Ta an olo
20
, Howa d Te ebelo
21
,
Shiyi Yang
22
, Jianping Wang
22
, I o Nnane
22
, Ming Qi
22
,
Michele Kosh
22
, Ma ia Delioukina
22
and Ha mu Goldschmid
23
1
Hema ology, Uni e si y Hospi al Hô el-Dieu, Nan es, F ance.
2
Icahn
School o Medicine a Moun Sinai, New Yo k, NY, USA.
3
Ins i u
Ca alà d’Oncologia and Ins i u Josep Ca e as, Hospi al Ge mans
T ias i Pujol, Ba celona, Spain.
4
Hospi al 12 de Oc ub e, H12O-CNIO,
Haema ological Malignancies Clinical Resea ch Uni , Uni e sidad
Complu ense, CIBERONC, Mad id, Spain.
5
Klinikum Chemni z,
Chemni z, Ge many.
6
Mayo Clinic Flo ida, Jackson ille, FL, USA.
7
Uni e si ae sklinikum Tuebingen de Ebe ha d-Ka ls-Uni e si ae ,
Ab eilung ue Inne e Medizin II, Tübingen, Ge many.
8
Hospi al La Fe,
School o Medicine and Den is y, Ca holic Uni e si y o Valencia,
Valencia, Spain.
9
CIBERONC, Ins i u o Ca los III, Mad id, Spain.
10
Hospi al Gene al Uni e si a io G ego io Ma añón (HGUGM), IiSGM,
Mad id, Spain.
11
Uni e si y Hospi al o Salamanca/IBSAL/Cance
Resea ch Cen e -IBMCC (USAL-CSIC), Salamanca, Spain.
12
Asklepios
Tumo zen um Hambu g, AK Al ona and AK S . Geo g, Hambu g,
Ge many.
13
Clínica Uni e sidad de Na a a, Pamplona, Spain.
14
Depa men o Hema ology, Hôpi al Hau Lé êque, Uni e si y
Hospi al, Pessac, F ance.
15
Depa men o Hema ology, Cen e
Hospi alie Lyon Sud, Hospices Ci ils de Lyon, Pie e-Béni e, F ance.
16
Hema ology Depa men , Ins i u Ca alà d’Oncologia - Hospi ale ,
IDIBELL, Uni e si y o Ba celona, Ba celona, Spain.
17
Hospi al
Uni e si a i Son Llà ze , IdISBa, Palma de Mallo ca, Illes Balea s,
Spain.
18
Se ice d’Héma ologie e Thé apie Cellulai e, Hôpi al
B e onneau, Cen e Hospi alie Régional Uni e si ai e (CHRU), Tou s,
F ance.
19
Hospi al Clínic de Ba celona, IDIBAPS, Ba celona, Spain.
20
Neb aska Cance Specialis s, Omaha, NE, USA.
21
P o idence Cance
Cen e , Sou hfield, MI, USA.
22
Janssen Resea ch & De elopmen , LLC,
Sp ing House, PA, USA.
23
GMMG-S udy G oup a Uni e si y Hospi al
Heidelbe g, In e nal Medicine V, Heidelbe g, Ge many.
✉email: philippe.mo eau@chu-nan es.
DATA AVAILABILITY
The da a sha ing policy o Janssen Pha maceu ical Companies o Johnson & Johnson
is a ailable a h ps://www.janssen.com/clinical- ials/ anspa ency. As no ed on his
si e, eques s o access o he s udy da a can be submi ed h ough Yale Open Da a
Access (YODA) P ojec si e a h p://yoda.yale.edu.
REFERENCES
1. DARZALEX
®
(da a umumab) injec ion, o in a enous use [package inse ].
Janssen Bio ech, Inc. 2022.
2. Eu opean Medicines Agency. DARZALEX 20 mg/mL concen a e o solu ion o
in usion [summa y o p oduc cha ac e is ics]. h ps://www.ema.eu opa.eu/en/
documen s/p oduc -in o ma ion/da zalex-epa -p oduc -in o ma ion_en.pd .
Accessed Oc 2022.
3. DARZALEX FASPRO
®
(da a umumab and hyalu onidase-fihj) injec ion, o sub-
cu aneous use [package inse ]. Janssen Bio ech, Inc. 2022.
4. Dimopoulos MA, Te pos E, Boccado o M, Delimpasi S, Beksac M, Ka od i ou E,
e al. APOLLO T ial In es iga o s. Da a umumab plus pomalidomide and
Co espondence
3
Blood Cance Jou nal (2023) 13:33
dexame hasone e sus pomalidomide and dexame hasone alone in p e iously
ea ed mul iple myeloma (APOLLO): an open-label, andomised, phase 3 ial.
Lance Oncol. 2021;22:801–12.
5. Ma eos MV, Sonne eld P, Hung ia V, Nooka AK, Es ell JA, Ba e o W, e al. Da -
a umumab, bo ezomib, and dexame hasone e sus bo ezomib and dex-
ame hasone in pa ien s wi h p e iously ea ed mul iple myeloma: h ee-yea
ollow-up o CASTOR. Clin Lymphoma Myeloma Leuk. 2020;20:509–18.
6. KYPROLIS
®
(ca filzomib) o injec ion, o in a enous use [package inse ]. Onyx
Pha maceu icals, Inc. 2021.
7. Dimopoulos M, Quach H, Ma eos MV, Landg en O, Leleu X, Siegel D, e al. Ca -
filzomib, dexame hasone, and da a umumab e sus ca filzomib and dex-
ame hasone o pa ien s wi h elapsed o e ac o y mul iple myeloma
(CANDOR): esul s om a andomised, mul icen e, open-label, phase 3 s udy.
Lance . 2020;396:186–97.
8. Usmani SZ, Quach H, Ma eos MV, Landg en O, Leleu X, Siegel D, e al. Ca filzomib,
dexame hasone, and da a umumab e sus ca filzomib and dexame hasone o
pa ien s wi h elapsed o e ac o y mul iple myeloma (CANDOR): upda ed ou -
comes om a andomised, mul icen e, open-label, phase 3 s udy. Lance Oncol.
2022;23:65–76.
9. Mo eau P, Ma eos MV, Be enson JR, Weisel K, Lazza o A, Song K, e al. Once
weekly e sus wice weekly ca filzomib dosing in pa ien s wi h elapsed and
e ac o y mul iple myeloma (A.R.R.O.W.): in e im analysis esul s o a ando-
mised, phase 3 s udy. Lance Oncol. 2018;19:953–64.
10. Mo eau P, Cha i A, Haenel M, O iol A, Rod iguez-O e o P, McCa hy H, e al.
Subcu aneous da a umumab (DARA SC) plus s anda d-o -ca e (SoC) egimens in
mul iple myeloma (MM) ac oss lines o he apy in he phase 2 PLEIADES s udy:
ini ial esul s o he DARA SC plus ca filzomib/dexame hasone (D-Kd) coho , and
upda ed esul s o he DARA SC plus bo ezomib/melphalan/p ednisone
(D-VMP) and DARA SC plus lenalidomide/dexame hasone (D-Rd) coho s. Blood.
2020;136:28–30.
11. Cha i A, Ma inez-Lopez J, Ma eos MV, Bladé J, Benboubke L, O iol A, e al.
Da a umumab plus ca filzomib and dexame hasone in pa ien s wi h elapsed o
e ac o y mul iple myeloma. Blood. 2019;134:421–31.
12. San-Miguel J, Usmani SZ, Ma eos MV, an de Donk NWCJ, Kau man JL, Mo eau P,
e al. Subcu aneous da a umumab in pa ien s wi h elapsed o e ac o y mul-
iple myeloma: Pa 2 o he open-label, mul icen e , dose-escala ion phase 1b
s udy (PAVO). Haema ologica. 2021;106:1725–32.
13. Ma eos MV, Nahi H, Legiec W, G osicki S, Vo obye V, Spicka I. e al. Subcu aneous
e sus in a enous da a umumab in pa ien s wi h elapsed o e ac o y mul iple
myeloma (COLUMBA): a mul icen e, open-label, non-in e io i y, andomised,
phase 3 ial. Lance Haema ol. 2020;7:e370–80.
14. Kuma SK, Maje I, Panjabi S, Medheka R, Campioni M, Dimopoulos MA. Cos -
e ec i eness o once weekly ca filzomib 70 mg/m
2
plus dexame hasone in
pa ien s wi h elapsed and e ac o y mul iple myeloma in he Uni ed S a es.
Expe Re Hema ol. 2020;13:687–96.
ACKNOWLEDGEMENTS
These s udies (ClinicalT ials.go Iden ifie s: NCT03412565 and NCT01998971) we e
sponso ed by Janssen Resea ch & De elopmen , LLC. We hank he pa ien s
pa icipa ing in he PLEIADES and EQUULEUS s udies and hei amilies, he s a
membe s a he s udy si es, he da a and sa e y moni o ing commi ees, and he s a
membe s who we e in ol ed in he da a collec ion and analyses. We also hank
Amgen o supplying he ca filzomib used in hese s udies. Medical w i ing and
edi o ial suppo we e p o ided by Lisa Shannon, Pha mD, o Lumani y Commu-
nica ions Inc., and we e unded by Janssen Global Se ices, LLC.
AUTHOR CONTRIBUTIONS
All au ho s in e p e ed he da a, e iewed he manusc ip , app o ed he final e sion,
decided o publish his epo , and ouch o he da a accu acy and comple eness.
COMPETING INTERESTS
PM ecei ed hono a ia om B is ol Mye s Squibb/Celgene, Janssen-Cilag, AbbVie,
Amgen, Takeda, Oncopep ides, Sanofi, and GlaxoSmi hKline. AC se ed as a
consul an o in an ad iso y ole o Amgen, Janssen Oncology, Sea le Gene ics,
Ka yopha m The apeu ics, Genzyme, Oncopep ides, Takeda, An engene, GlaxoS-
mi hKline, Secu a Bio, Sha uck Labs, Genen ech, AbbVie, and B is ol Mye s Squibb/
Celgene; and ecei ed esea ch unding om Celgene, Janssen, Amgen, Sea le
Gene ics, Takeda, and Pha macyclics. AO se ed on ad iso y boa ds o Sanofi,
GlaxoSmi hKline, B is ol Mye s Squibb, Amgen, and Janssen. JM-L consul ed o ,
ecei ed hono a ia om, and se ed on a boa d o di ec o s o ad iso y commi ees
o Janssen; consul ed o and ecei ed esea ch unding om B is ol Mye s Squibb
and Incy e; and consul ed o No a is. MH ecei ed hono a ia om Amgen, No a is,
Roche, Celgene, Takeda, and Baye . CT ecei ed hono a ia om and se ed in a
consul ing o ad iso y ole o Janssen, Celgene, Takeda, Amgen, and AbbVie; and
had a el, accommoda ions, o o he expenses paid o eimbu sed by Janssen,
Takeda, Amgen, and AbbVie. SA se ed as a consul an o GlaxoSmi hKline, Sanofi,
B is ol Mye s Squibb, Takeda, BeiGene, Pha macyclics, Amgen, and Janssen; and
ecei ed esea ch unding om GlaxoSmi hKline, B is ol Mye s Squibb, Pha macyclics,
Amgen, Janssen, Cellec a , Xenco , and AbbVie. BB ecei ed hono a ia om Janssen,
Amgen, Takeda, and Sanofi. JdlRC ecei ed hono a ia om B is ol Mye s Squibb/
Celgene, Jansen-Cilag, Amgen, Takeda, Sanofi, and GlaxoSmi hKline; and ecei ed
a el suppo om Janssen-Cilag. CE ecei ed hono a ia om B is ol Mye s Squibb/
Celgene, Janssen-Cilag, Amgen, Sanofi, and GlaxoSmi hKline. M-VM ecei ed
hono a ia de i ed om lec u es and pa icipa ion in ad iso y boa ds om Janssen,
Celgene, Takeda, Amgen, GlaxoSmi hKline, AbbVie, Pfize , Regene on, Adap i e
Bio echnologies, Roche, and Sea le Genen ech. HS ecei ed hono a ia om B is ol
Mye s Squibb/Celgene, Janssen-Cilag, AbbVie, Amgen, Takeda, Oncopep ides, Sanofi,
and GlaxoSmi hKline; and ecei ed a el suppo om B is ol Mye s Squibb/Celgene,
Janssen-Cilag, AbbVie, Amgen, Sanofi, and GlaxoSmi hKline. PR-O pa icipa ed in
speake s bu eaus o and ecei ed hono a ia om B is ol Mye s Squibb/Celgene,
Janssen, Amgen, GlaxoSmi hKline, Sanofi, Regene on, and Oncopep ides. CH
ecei ed hono a ia om Janssen, B is ol Mye s Squibb, Amgen, Takeda, and AbbVie.
LK se ed on ad iso y boa ds o and/o ecei ed hono a ia o a el suppo om
Celgene/B is ol Mye s Squibb, Janssen, Takeda, Amgen, and GlaxoSmi hKline. ASB
se ed as a consul an o , ecei ed hono a ia om, and pa icipa ed in speake s
bu eaus o Takeda. LR ecei ed hono a ia om Janssen, Celgene, Amgen, Takeda,
Sanofi, and GlaxoSmi hKline. HT se ed on an ad iso y boa d o B is ol Mye s
Squibb; and pa icipa ed in speake s bu eaus o ADP. SY, JW, IN, MQ, and MK a e
employees o Janssen Resea ch & De elopmen , LLC, and may hold equi y. MD was
employed by Janssen Resea ch & De elopmen , LLC, a he ime o he s udy. HG
ecei ed g an s and/o p o ision o In es iga ional Medicinal P oduc s om Amgen,
B is ol Mye s Squibb, Celgene, Chugai, Die ma Hopp Founda ion, Janssen, Johns
Hopkins Uni e si y, and Sanofi; ecei ed esea ch suppo om Amgen, B is ol Mye s
Squibb, Celgene, Chugai, Janssen, Incy e, Molecula Pa ne s, Me ck Sha p & Dohme,
Sanofi, Mundipha ma GmbH, Takeda, and No a is; se ed on ad iso y boa ds o
Adap i e Bio echnologies, Amgen, B is ol Mye s Squibb, Celgene, Janssen, Sanofi,
and Takeda; and ecei ed hono a ia om Amgen, B is ol Mye s Squibb, Celgene,
Chugai, GlaxoSmi hKline, Janssen, No a is, and Sanofi. JB, LB, and ST ha e no hing o
disclose.
ADDITIONAL INFORMATION
Supplemen a y in o ma ion The online e sion con ains supplemen a y ma e ial
a ailable a h ps://doi.o g/10.1038/s41408-023-00805-x.
Co espondence and eques s o ma e ials should be add essed o Philippe Mo eau.
Rep in s and pe mission in o ma ion is a ailable a h p://www.na u e.com/
ep in s
Publishe ’s no e Sp inge Na u e emains neu al wi h ega d o ju isdic ional claims
in published maps and ins i u ional a filia ions.
Open Access This a icle is licensed unde a C ea i e Commons
A ibu ion 4.0 In e na ional License, which pe mi s use, sha ing,
adap a ion, dis ibu ion and ep oduc ion in any medium o o ma , as long as you gi e
app op ia e c edi o he o iginal au ho (s) and he sou ce, p o ide a link o he C ea i e
Commons license, and indica e i changes we e made. The images o o he hi d pa y
ma e ial in his a icle a e included in he a icle’s C ea i e Commons license, unless
indica ed o he wise in a c edi line o he ma e ial. I ma e ial is no included in he
a icle’s C ea i e Commons license and you in ended use is no pe mi ed by s a u o y
egula ion o exceeds he pe mi ed use, you will need o ob ain pe mission di ec ly
om he copy igh holde . To iew a copy o his license, isi h p://
c ea i ecommons.o g/licenses/by/4.0/.
© The Au ho (s) 2023
Co espondence
4
Blood Cance Jou nal (2023) 13:33